Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PPI 1011

Next Previous
Drug Profile

PPI 1011

Alternative Names: Ethanolamine plasmalogen precursor - Phenomenome Discoveries; Ether glycerophosphoethanolamine lipid precursor - Phenomenome Discoveries; Ether lipid precursor - Phenomenome Discoveries; PlsEtn precursor - Phenomenome Discoveries; PPI-1011

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenomenome Discoveries
  • Developer GraySpace Therapeutics; Phenomenome Discoveries
  • Class 1 ring heterocyclic compounds; Esters; Ethers; Omega 3 fatty acids; Plasmalogens
  • Mechanism of Action Plasmalogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rhizomelic chondrodysplasia punctata
  • Preclinical Alzheimer's disease; Dyskinesias; Parkinson's disease
  • Discontinued Pelizaeus-Merzbacher disease

Most Recent Events

  • 17 Oct 2025 PPI 1011 is still in preclinical trials for Alzheimer's disease, Dyskinesias and Parkinson's disease in Canada (Med-Life Discoveries pipeline, October 2025)
  • 17 Oct 2025 Med-Life Discoveries plans early-stage efficacy studies for PPI 1011 (Med-Life Discoveries pipeline, October 2025)
  • 29 May 2023 Phase-I clinical trials in Rhizomelic chondrodysplasia punctata in Canada (PO) (NCT05969977)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top